Note 14 - Research and Development Expenses -Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Consultants and subcontractors | $ 100 | $ 25 | $ 177 | $ 48 |
| Depreciation | 4 | 0 | 8 | 0 |
| Clinical trials | 0 | 0 | 0 | 19 |
| Expenses - other | 63 | 50 | 178 | 74 |
| Total | 878 | 392 | 1,517 | 712 |
| Research and Development Expense [Member] | ||||
| Salary and employee benefits | $ 711 | $ 317 | $ 1,154 | $ 571 |
| X | ||||||||||
- Definition Represents the amount of expense from clinical trials incurred during the period. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of consulting and subcontracting expense incurred during the period. No definition available.
|
| X | ||||||||||
- Definition The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|